80岁及以上女性骨折风险与骨折前死亡风险的平衡
本研究基于SOF和HABC研究中4895名80岁及以上女性,分别建立非脊柱骨折(NSF)和骨折前死亡的竞争风险预测模型。结果显示,NSF的预测因子与骨折前死亡的预测因子不同,且5年NSF风险相似的女性中骨折前死亡风险差异很大,提示骨折风险和预期寿命均应纳入骨质疏松药物治疗的共同决策。
要点
- NSF与骨折前死亡的预测因子不同,需分别评估。
- 5年NSF风险相似的女性中,骨折前死亡风险差异显著。
- 骨质疏松药物决策应同时考虑骨折风险和预期寿命。
核心结论
- 在80岁及以上女性中,5年非脊柱骨折风险相似者其骨折前死亡风险存在很大差异。
- 骨折风险和预期寿命均应纳入80岁及以上女性骨质疏松药物治疗起始或继续的共同临床决策。
研究设计与样本
- 基于SOF和HABC研究中4895名80岁及以上女性的前瞻性队列,分别建立非脊柱骨折和骨折前死亡的竞争风险预测模型。
- 采用修改的竞争风险比例风险模型识别预测因子,并估计5年累积发生率。
- 重复上述过程建立髋部骨折和髋部骨折前死亡的预测模型。
主要发现
- NSF的显著预测因子包括种族、全髋骨密度、握力、既往骨折、跌倒及使用SSRI、苯二氮䓬类或口服/透皮雌激素。
- 骨折前死亡的显著预测因子包括年龄、步行速度、多病共存、体重变化、身体消瘦、吸烟、自评健康、痴呆及使用华法林。
- 按风险三分位定义的九个亚组中,5年结局从高风险NSF/低风险死亡亚组的28% NSF和8%死亡,到低风险NSF/高风险死亡亚组的9% NSF和22%死亡。
- 髋部骨折及其前死亡的预测因子结果与NSF类似。
关键数值与推荐
- NSF预测因子与骨折前死亡预测因子不同,提示需分别评估两种风险。
- 5年NSF风险相似的女性中,骨折前死亡风险差异显著(如28% NSF/8%死亡 vs 9% NSF/22%死亡)。
临床怎么用
- 对80岁及以上女性,在启动或继续骨质疏松药物治疗前,应同时评估骨折风险和预期寿命。
- 骨折风险高但死亡风险低的女性可能更多从骨质疏松药物中获益。
- 骨折风险低但死亡风险高的女性可能需谨慎权衡药物治疗的获益与负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most fractures occur in women aged ≥80 years but competing mortality unrelated to fracture may limit the benefit of osteoporosis drug therapy for some women in late life. Our primary aim was to develop separate prediction models for non-spine fracture (NSF) and mortality before fracture to identify subsets of women with varying fracture versus mortality risks. METHODS: Separate prediction models were developed for NSF and mortality before NSF for 4895 women aged ≥80 years enrolled in the Study of Osteoporotic Fractures (SOF) or the Health Aging and Body Composition (HABC) study. Proportional hazards models modified to account for competing mortality were used to identify candidate risk factors for each outcome. Predictors associated with NSF or mortality (p < 0.2) were included in separate competing risk models to estimate the cumulative incidence of NSF and mortality before NSF during 5 years of follow-up. This process was repeated to develop separate prediction models for hip fracture and mortality before hip fracture. RESULTS: Significant predictors of NSF (race, total hip BMD, grip strength, prior fracture, falls, and use of selective serotonin reuptake inhibitors, benzodiazepines, or oral/transdermal estrogen) differed from predictors of mortality before NSF (age, walking speed, multimorbidity, weight change, shrinking, smoking, self-rated health, dementia, and use of warfarin). Within nine subsets of women defined by tertiles of risk, 5-year outcomes varied from 28% NSF and 8% mortality in the high-risk NSF/low-risk mortality subset, to 9% NSF and 22% mortality in the low-risk NSF/high-risk mortality subset. Similar results were seen for predictors of hip fracture and mortality before hip fracture. CONCLUSION: Considerable variation in 5-year competing mortality risk is present among women in late life with similar 5-year NSF risk. Both fracture risk and life expectancy should inform shared clinical decision-making regarding initiation or continuation of osteoporosis drug therapy for women aged ≥80 years.
引用
- Schousboe JT, Langsetmo L, Fink HA, et al. Balancing fracture risk versus risk of mortality before fracture among women aged 80 years or older. J Am Geriatr Soc. 2024. PMID: 38450585. doi:10.1111/jgs.18859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。